Komipharm International Statistics

Total Valuation

Komipharm International has a market cap or net worth of KRW 277.11 billion. The enterprise value is 299.49 billion.

Market Cap	277.11B
Enterprise Value	299.49B

Important Dates

The last earnings date was Wednesday, November 6, 2024.

Earnings Date	Nov 6, 2024
Ex-Dividend Date	n/a

Share Statistics

Komipharm International has 69.28 million shares outstanding. The number of shares has decreased by -2.72% in one year.

Current Share Class	n/a
Shares Outstanding	69.28M
Shares Change (YoY)	-2.72%
Shares Change (QoQ)	-0.74%
Owned by Insiders (%)	40.38%
Owned by Institutions (%)	3.15%
Float	40.96M

Valuation Ratios

The trailing PE ratio is 24.37.

PE Ratio	24.37
Forward PE	n/a
PS Ratio	5.07
PB Ratio	4.24
P/TBV Ratio	n/a
P/FCF Ratio	106.02
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 49.21, with an EV/FCF ratio of 114.58.

EV / Earnings	26.41
EV / Sales	5.49
EV / EBITDA	49.21
EV / EBIT	98.70
EV / FCF	114.58

Financial Position

The company has a current ratio of 1.31, with a Debt / Equity ratio of 0.62.

Current Ratio	1.31
Quick Ratio	0.80
Debt / Equity	0.62
Debt / EBITDA	7.21
Debt / FCF	16.80
Interest Coverage	0.99

Financial Efficiency

Return on equity (ROE) is 19.70% and return on invested capital (ROIC) is 1.66%.

Return on Equity (ROE)	19.70%
Return on Assets (ROA)	1.46%
Return on Capital (ROIC)	1.66%
Revenue Per Employee	345.13M
Profits Per Employee	71.77M
Employee Count	158
Asset Turnover	0.42
Inventory Turnover	2.11

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -30.34% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-30.34%
50-Day Moving Average	4,137.80
200-Day Moving Average	4,189.23
Relative Strength Index (RSI)	37.14
Average Volume (20 Days)	68,894

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Komipharm International had revenue of KRW 54.53 billion and earned 11.34 billion in profits. Earnings per share was 164.14.

Revenue	54.53B
Gross Profit	19.31B
Operating Income	3.03B
Pretax Income	13.22B
Net Income	11.34B
EBITDA	6.09B
EBIT	3.03B
Earnings Per Share (EPS)	164.14

Full Income Statement

Balance Sheet

The company has 27.46 billion in cash and 43.90 billion in debt, giving a net cash position of -16.45 billion or -237.39 per share.

Cash & Cash Equivalents	27.46B
Total Debt	43.90B
Net Cash	-16.45B
Net Cash Per Share	-237.39
Equity (Book Value)	71.29B
Book Value Per Share	943.39
Working Capital	16.52B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.29 billion and capital expenditures -672.75 million, giving a free cash flow of 2.61 billion.

Operating Cash Flow	3.29B
Capital Expenditures	-672.75M
Free Cash Flow	2.61B
FCF Per Share	37.73

Full Cash Flow Statement

Margins

Gross margin is 35.41%, with operating and profit margins of 5.56% and 20.79%.

Gross Margin	35.41%
Operating Margin	5.56%
Pretax Margin	24.24%
Profit Margin	20.79%
EBITDA Margin	11.16%
EBIT Margin	5.56%
FCF Margin	4.79%

Dividends & Yields

Komipharm International does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.72%
Shareholder Yield	2.72%
Earnings Yield	4.10%
FCF Yield	0.94%

Stock Splits

The last stock split was on August 17, 2023. It was a forward split with a ratio of 1.1006894.

Last Split Date	Aug 17, 2023
Split Type	Forward
Split Ratio	1.1006894

Scores

Komipharm International has an Altman Z-Score of 3.52.

Altman Z-Score	3.52
Piotroski F-Score	n/a